How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | GILDGILEAD SCIENCES, INC. | 950160.KQ950160.KQ | 950220.KQ950220.KQ | ABBVAbbVie Inc. | Median of the restexcluding GILD |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $157.19▲ 3.62 (2.36%) | ₩15420.00▲ 1100.00 (7.68%) | ₩1600.00▼ 150.00 (8.57%) | $285.19▲ 0.39 (0.14%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 9.0/10 | 3.3/10 | 2.0/10 | 7.0/10 | 3.3/10 |
| Market value | $195.07B | $261.33B | $10.73B | $503.46B | |
| Revenue | $29.44B | $5.16B | $94.8M | $61.16B | |
| Profit | $8.51B | -$192.59B | -$31.80B | $4.23B | |
| Revenue growthChange in sales versus the prior year. | 2.4% | 1.7% | -44.3% | 8.6% | 1.7% |
| Gross marginShare of sales left after the direct cost of producing them. | 78.8% | 13.3% | 100.0% | 70.2% | 70.2% |
| Operating marginShare of sales left after running the business, before interest and tax. | 34.0% | -432.7% | -26596.5% | 24.6% | -432.7% |
| Profit marginProfit kept from each dollar of sales. | 28.9% | -3733.3% | -33531.4% | 6.9% | -3733.3% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 32.1% | -2742.6% | -34003.6% | 29.1% | -2742.6% |
| Return on equityProfit against the owners' stake in the company. | 37.5% | -300.5% | -53.7% | -129.2% | -129.2% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 21.7% | -25.0% | -71.1% | 16.5% | -25.0% |
| P/E ratioPrice paid per dollar of annual profit. | 22.92x | — | — | 119.13x | 119.13x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | 20.44x | — | — | 35.69x | 35.69x |
| Price to book | 8.59x | 4.08x | 0.18x | -153.96x | 0.18x |
| Debt to equityTotal liabilities compared with owners' stake. | 1.60x | 5.62x | 0.39x | -41.97x | 0.39x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 8/9 | 3/8 | 3/8 | 8/9 | 3.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | distress | distress | grey |
How GILD compares with the others
- GILD's operating margin of 34.0% is higher than the median of the other companies selected (-432.7%).
- Its revenue growth of 2.4% is in line with the median of the other companies selected (1.7%).
- It trades at a lower P/E than the other company selected: 22.9x against 119.1x.
- Its liabilities are higher relative to equity than the median of the other companies selected: 1.6x against 0.4x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.